Editas Medicine (EDIT) Expected to Announce Earnings on Wednesday

Editas Medicine (NASDAQ:EDIT) will likely be releasing its earnings data before the market opens on Wednesday, February 26th. Analysts expect Editas Medicine to post earnings of ($0.43) per share and revenue of $37.17 million for the quarter.

Editas Medicine Price Performance

NASDAQ:EDIT opened at $1.74 on Wednesday. The stock has a market cap of $143.64 million, a P/E ratio of -0.68 and a beta of 1.94. Editas Medicine has a one year low of $1.12 and a one year high of $11.58. The company has a fifty day moving average price of $1.34 and a 200 day moving average price of $2.62.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. JPMorgan Chase & Co. cut shares of Editas Medicine from a “neutral” rating to an “underweight” rating in a research note on Monday, December 16th. Raymond James cut shares of Editas Medicine from an “outperform” rating to a “market perform” rating in a research note on Monday, November 4th. Robert W. Baird dropped their price objective on shares of Editas Medicine from $10.00 to $8.00 and set an “outperform” rating for the company in a research note on Friday, December 13th. Chardan Capital restated a “neutral” rating on shares of Editas Medicine in a research note on Friday, December 13th. Finally, Barclays dropped their price objective on shares of Editas Medicine from $5.00 to $3.00 and set an “equal weight” rating for the company in a research note on Friday, December 13th. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $7.00.

About Editas Medicine

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.